 SHANGHAI, China, April 12, 2022 GLOBE NEWSWIRE -- Clover Biopharmaceuticals, Ltd. Clover; HKEX: 02197, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that Igor Smolenov, Senior Vice President, Global Clinical Development, will deliver a presentation at the World Vaccine Congress Washington 2022. The presentation will include data on SCB-2019 CpG 1018Alum, Clovers adjuvanted protein-based COVID-19 vaccine candidate. 